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EDUCATIONAL OBJECTIVES OVERVIEW

EPIDEMIOLOGY
The most recent and largest (N > 43,000) comorbidity study to date, the National Epidemiological Survey on Alcohol and Related Conditions (NESARC), found that 17.7% of respondents with a current SUD also met criteria for an anxiety disorder. 1 Treatment-seeking samples also demonstrate high rates of comorbid anxiety and SUDs. One study of 422 outpatients in the United States with opioid use disorders reported that 12% of men and 21% of women met criteria for a lifetime anxiety disorder. 2 Merikangas and colleagues 3 found that, in general, anxiety disorders precede the development of co-occurring alcohol (57% to 80%) and drug (67.6% to 100%) use disorders. 
SCREENING AND DIFFERENTIAL DIAGNOSIS
One of the greatest diffi culties in the area of co-occurring anxiety and SUDs is that of differential diagnosis. Substances of abuse impact the neurotransmitter systems involved in the pathophysiology of anxiety disorders and may unmask vulnerability or lead to organic changes that manifest as an anxiety disorder. The best way to differentiate substance-induced, transient symptoms of anxiety from anxiety disorders that warrant treatment is through observation of symptoms during a period of abstinence. Transient substance-induced symptoms improve with time. The duration of abstinence necessary for accurate diagnosis remains controversial and is likely to be based on both the diagnosis being assessed and the substance used. Long half-life drugs (eg, some benzodiazepines, methadone) may require several weeks of abstinence for withdrawal symptoms to subside. However, shorter-acting substances (eg, alcohol, cocaine, short half-life benzodiazepines) require shorter periods of abstinence to make valid diagnoses. A family history of anxiety disorder, the onset of anxiety symptoms before the onset of the SUD, and sustained anxiety symptoms during lengthy periods of abstinence all suggest an anxiety disorder that will need to be addressed with specifi c treatment.
ETIOLOGIC CONNECTIONS
A number of recent studies have focused on exploration of the etiologic relationships between anxiety and SUDs. Studies do not consistently support "self-medication" as an explanation for the relationship between anxiety and substance use. Although some substances can provide short-term relief of anxiety symptoms, in general there is anxiety induction with chronic substance use and withdrawal, which can initiate a feedforward cycle of increasing anxiety symptoms and substance consumption. 4 In the basic science arena, the role of neuroadaptation and stress in relapse to substance use has been an area of intense investigation. Corticotrophin releasing hormone (CRH), one of the key hormones involved in the stress response, has been implicated in the pathophysiology of anxiety, as well as in addictive disorders. 5 Noradrenergic and other neurotransmitter systems, as well as endogenous opiates, may One of the greatest diffi culties in the area of co-occurring anxiety and SUDs is that of differential diagnosis.
also provide a neurobiologic link between anxiety and substance use disorders.
GENERAL TREATMENT CONSIDERATIONS
In general, treatment efforts addressing anxiety disorders and SUDs have developed in parallel. The integration of effective treatments from both fi elds will be critical to the optimal treatment of individuals with co-occurring disorders. It is important to maximize the use of nonpharmacologic treatments. Learning strategies to selfregulate anxiety symptoms can interrupt the "self-medication" cycle and help individuals to acquire alternative coping strategies. Among psychosocial treatments, cognitive behavioral therapies (CBT) are among the most effective for both anxiety disorders and SUDs. Promising pilot work investigating the integration of treatments to develop therapies specifi cally targeting co-occurring disorders will be discussed in the sections that follow.
Research investigating pharmacotherapeutic treatments for both SUDs and anxiety disorders is progressing rapidly. The pharmacotherapeutic treatment of specifi c anxiety disorders will be discussed, but there are some general issues that apply to the treatment of co-occurring disorders, which will be discussed in this section. First, individuals in recovery from SUDs may have complex and confl icting feelings about the use of medications and may see the need for medications as a sign of defectiveness or failure. It is important to proactively discuss feelings and attitudes about medications and emphasize the need for medication adherence before prescribing. In cases where the relationship of psychiatric symptoms and substance use is unclear, the risk/benefi t ratio of using medications must be carefully considered. When medications are used, treatment should generally follow routine clinical practice for treatment of the anxiety disorder with some exceptions. It is important to consider potential toxic interactions between the prescription medications and substances of abuse, in case relapse should occur. It is also important to use the agent with the least abuse potential. Despite their effectiveness in immediate relief of panic and other anxiety symptoms, benzodiazepines are generally not considered a "fi rst-line" of treatment for SUD patients because of abuse potential. They may be considered as adjunctive medication during the early treatment phase when activation or latency of onset of the antidepressants is an issue. If a benzodiazepine is prescribed to a patient with a co-occurring SUD, close monitoring for relapse and limited amounts of medication should be given. Medication adherence contracts, similar to those used with chronic pain patients receiving prescription opioids, may also be useful in patients with a co-occuring SUD.
Finally, the use of agents specifi cally targeting SUDs in individuals with co-occurring anxiety disorders is under-explored. In one study of 254 outpatients with alcohol dependence and a variety of comorbid psychiatric disorders, Petrakis and colleagues 6 investigated the effi cacy of disulfi ram and naltrexone, or their combination, in a 12-week randomized trial. Participants treated with either medication had signifi cantly more consecutive weeks of abstinence and fewer drinking days per week. The effects of the medications by specifi c comorbid psychiatric disorder were not discussed, but active medication was associated with greater anxiety symptom improvement. No clear advantage of combining medications was observed.
In the sections that follow, the prevalence rates, differential diagnosis and treatment of specifi c anxiety disorders will be briefl y reviewed.
SPECIFIC DISORDERS
Generalized Anxiety Disorder
SUDs are one of the most common comorbid psychiatric disorders among individuals with generalized anxiety disorder (GAD). 7 A recent epidemiologic study of 5,877 adults found that GAD was the anxiety disorder most often associated with using alcohol or drugs to self-medicate symptoms. 8 Comorbid GAD is associated with an accelerated progression from fi rst use to the onset of dependence, 9 and the presence of comorbid SUDs has been shown to signifi cantly decrease the likelihood of recovery from GAD. 10 As GAD symptoms can be mimicked by substance use or withdrawal, diagnostic complications can arise. Assessment of GAD should be delayed until intoxication or withdrawal has terminated. For short-acting drugs (eg, cocaine), it may be possible to assess GAD after one week of abstinence, but longer periods of time (eg, 4 to 8 weeks) may be required for longeracting drugs (eg, methadone, valium).
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Patients should also be assessed for use of over-the-counter substances that can induce anxiety (eg, caffeine, diet pills). The Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV), requires that a core number of anxiety symptoms be present for at least 6 months in order to meet diagnostic criteria for GAD. Substance use during those 6 months needs to be considered. Symptoms of GAD must have been present dur-
In general, treatment efforts addressing anxiety disorders and SUDs have developed in parallel.
ing times other than when the patient was using or recovering from alcohol or drugs. This can be challenging to assess because many SUD patients presenting for treatment and complaining of anxiety will not have had 6 months of abstinence. The treatment of GAD in the context of addiction can also be challenging. Although benzodiazepines are effective in the treatment of GAD, their use in individuals with current or former SUDs is controversial because of their abuse liability. Some authors suggest, however, that the empirical evidence regarding these concerns is lacking. They also suggest that benzodiazepines may be safely used to treat anxiety disorders in some SUD patients. 12 Buspirone, a partial 5-hydroxytryptamine [5-HT]1A agonist with low abuse potential, has been shown to be effi cacious in some studies in anxious alcoholics, 11, 13, 14 but the results are mixed. 15, 16 Selective serotonin reuptake inhibitors (SSRIs) are effi cacious in reducing GAD symptoms; 17 however, no clinical trials of SSRIs among comorbid GAD/SUD patients have been conducted.
Among psychosocial treatments, CBT may help decrease both anxiety symptoms and risk of relapse. Patients with both GAD and SUDs may benefi t from education surrounding relaxation techniques, coping skills, cognitive restructuring, behavioral activation, problem solving, and sleep hygiene. 11 Nutritional counseling and regular exercise may also prove to be benefi cial for GAD/SUD patients, although empirical trials are lacking.
Posttraumatic Stress Disorder
The National Comorbidity Study (NCS) found that adults with posttraumatic stress disorder (PTSD) were two to four times more likely to have a comorbid SUD as compared with those without PTSD. 18 Similarly, data from a more recent multisite longitudinal study of almost 1,000 individuals showed that a history of PTSD predisposes individuals to elevated rates of drug abuse and dependence. 19 Among treatment-seeking substance abusers, the prevalence of lifetime PTSD has been reported as high as 50% or greater. 20 In the majority of cases, the development of PTSD precedes the development of the SUD. 21 In comparison with other anxiety disorders, there is greater empirical research on the treatment of comorbid PTSD and SUDs. In a double-blind, placebo-controlled, 12-week trial, Brady and colleagues 22 investigated the use of sertraline, which has been approved by the Food and Drug Administration (FDA) for the treatment of PTSD. The study included 94 individuals with PTSD and alcohol dependence. Individuals with less severe alcohol dependence and early onset PTSD demonstrated greater improvement in alcohol use severity when treated with sertraline as compared to placebo. Among 254 outpatients with alcohol dependence and comorbid psychiatric disorders (42.9% met DSM-IV criteria for comorbid PTSD), Petrakis and colleagues6 found that patients treated with naltrexone or disulfi ram, as compared with placebo, had more consecutive weeks of abstinence and fewer drinking days per week. In comparison with naltrexone-treated participants, disulfi ram-treated participants reported less craving from pre-to post-treatment. No clear advantage of combining disulfi ram and naltrexone was observed.
A number of investigations of integrative psychotherapies have demonstrated that addressing trauma/PTSD among SUD patients is benefi cial and typically leads to signifi cant reductions in both PTSD and SUD symptoms. The most widely studied integrated therapy to date is Seeking Safety (SS), a 25-session, manualized treatment that provides psychoeducation and teaches coping skills. 23 In a controlled study, 24 107 women were randomized to SS, relapse prevention (RP), or treatmentas-usual (TAU). Patients who received TAU failed to show improvement (and in the case of PTSD symptoms, worsened over time), while patients who received either SS or RP demonstrated signifi cant improvement in substance use, PTSD, and global psychiatric symptoms. No signifi cant difference between SS and RP treatment groups were observed.
To date, two small studies have systematically examined treatments that integrate gold-standard exposure-based techniques for PTSD with empirically validated treatments for SUDs. Triffl eman and colleagues developed a 20-week, manualized treatment that utilizes RP, coping skills, psychoeducation, and in vivo exposure. In a small (N = 19) pilot trial it was shown to be as effective as, but not superior to, Twelve-Step Facilitation Therapy with regard to PTSD symptoms and drug use. 25 In another uncontrolled trial (N = 39), Brady and colleagues 26 developed a 16-session, manualized treatment consisting of combined imaginal and in vivo exposure therapy for PTSD and cognitive-behavioral RP techniques for cocaine dependence. The intervention was associated with signifi cant reductions in all three clusters of PTSD symptoms and cocaine use. Several other studies have preliminarily explored the use of psychosocial treatments among SUD/ SUDs are one of the most common comorbid psychiatric disorders among individuals with generalized anxiety disorder.
PTSD patients with favorable results. 27, 28 Although more randomized, controlled trials in this area are needed, the studies to date demonstrate that for the majority of SUD/PTSD patients, addressing PTSD confers substantial therapeutic benefi ts.
Social Phobia
Data from the NCS found that 16.4% of socially phobic individuals endorsed self-medicating with alcohol and drugs. 29 Individuals with social phobia (SP) are two to three times more likely than individuals without SP to develop an alcohol use disorder. 30 As the average onset of social phobia is before adolescence, symptoms of social anxiety typically precede the initiation of alcohol or drug use. 31 In a placebo-controlled trial, Randall and colleagues 32 examined the effectiveness of paroxetine, an SSRI, in 15 outpatients with alcohol dependence and SP. The paroxetine-treated group had significantly lower SP symptoms at the end of the 8-week trial, as compared with the placebo group; however, no signifi cant group differences in measures of alcohol use severity were revealed. Gabapentin is an anticonvulsant agent with demonstrated effi cacy in the treatment of SP. 33 This is of particular interest because gabapentin has also demonstrated effi cacy in the treatment of alcohol withdrawal 34 and unlike benzodiazepines, gabapentin has no abuse potential. One case report of a polysubstance-dependent individual with comorbid SP who was treated with gabapentin documented signifi cant improvement in craving and substance use, 35 but there are currently no controlled trials examining the effi cacy of gabapentin in co-occurring SP and SUDs.
Several controlled trials have examined the effi cacy of psychosocial treatments for SP/SUD patients. In 93 outpatients with comorbid SP and alcohol dependence, Randall and colleagues 36 compared a 12-week, manual-based CBT for alcohol dependence with an integrated manualbased CBT for both disorders. Contrary to expectations, patients who received the alcohol dependence-only treatment evidenced better outcomes than patients who received the integrated treatment. Although the reasons for this unexpected fi nding are unclear, the authors hypothesized that exposure to feared social situations during early recovery may have led to increases in alcohol use to cope. Schade and colleagues 37 randomly assigned 96 individuals with alcohol dependence and comorbid SP and/or agoraphobia to receive relapse prevention (RP), or RP plus CBT for the anxiety disorder. The majority (89/96) of the sample had SP. Both groups were offered concomitant SSRI pharmacotherapy (fl uvoxamine), but almost half (53%) refused it. Individuals who received the combined psychosocial treatment (alcohol + anxiety) had signifi cantly greater improvement in anxiety symptoms than those who received treatment addressing alcohol dependence only. No signifi cant differences between groups in alcohol use severity were observed and the use of fl uvoxamine was not associated with improved anxiety or alcohol use severity outcomes.
Obsessive-compulsive Disorder
In comparison with other anxiety disorders, the association between obsessive compulsive disorder (OCD) and SUDs is less robust. 38 For example, in a clinical sample of 254 individuals, approximately 4% of OCD patients met criteria for a lifetime SUD. 39 The lower rates of OCD among SUD patients may be due, in part, to the generally low levels of impulsive or spontaneous behaviors and high levels of harm avoidance exhibited among individuals with OCD. When OCD patients do use substances, they typically choose sedating agents (eg, alcohol, marijuana).
Some substances of abuse (eg, alcohol, stimulants) and medications (eg, benzodiazepines) can produce obsessive-compulsive behaviors. 11, 40 This potential confound should be ruled out when diagnosing OCD among SUD patients. In general, the differential diagnosis of OCD in individuals with SUDs is not as diffi cult as that of some of the other anxiety disorders because there is less symptom overlap. For SUD patients, the content of obsessions and compulsions is restricted to alcohol or drug use. Obsessions and compulsions focused on procuring and using drugs alone, or that occur only during intoxication, do not meet diagnostic criteria for OCD.
Little research on the treatment of cooccurring OCD and SUDs has been conducted to date. There are no randomized controlled trials examining the use of a pharmacologic treatment for this patient population. SSRIs have been shown to be effective in treating OCD among nonsubstance dependent patients 41 and would likely be helpful among SUD patients, but this has not been systematically tested. One controlled clinical trial has demonstrated promising results for an integrated OCD/ SUD psychotherapy. 42 
CONCLUSIONS
Interest in the co-occurrence of anxiety disorders and SUDs has grown tremendously in recent years, as the evidence of the prevalence and impact of comorbidity has become increasingly clear. There have been a number of recent advances in the treatment of both anxiety disorders and SUDs, and treatment addressing both disorders can improve long-term therapeutic outcomes. Specifi c considerations in choosing a pharmacologic agent for use in patients with SUDs include safety, toxicity, and abuse liability. In conclusion, although the co-occurrence of SUDs and anxiety disorders is an important area in which recent developments provide cause for considerable optimism, much work remains to be done.
